202 related articles for article (PubMed ID: 22290393)
1. Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.
Heindl S; Eggenstein E; Keller S; Kneissl J; Keller G; Mutze K; Rauser S; Gasteiger G; Drexler I; Hapfelmeier A; Höfler H; Luber B
J Cancer Res Clin Oncol; 2012 May; 138(5):843-58. PubMed ID: 22290393
[TBL] [Abstract][Full Text] [Related]
2. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
Kneissl J; Keller S; Lorber T; Heindl S; Keller G; Drexler I; Hapfelmeier A; Höfler H; Luber B
Int J Oncol; 2012 Aug; 41(2):733-44. PubMed ID: 22614881
[TBL] [Abstract][Full Text] [Related]
3. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.
Shi M; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2014; 14(2):217-24. PubMed ID: 24467518
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
6. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
7. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
9. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.
Song N; Liu S; Zhang J; Liu J; Xu L; Liu Y; Qu X
Int J Mol Sci; 2014 Apr; 15(4):5838-51. PubMed ID: 24714091
[TBL] [Abstract][Full Text] [Related]
11. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
13. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.
Park JE; Jin MH; Hur M; Nam AR; Bang JH; Won J; Oh DY; Bang YJ
Gastric Cancer; 2019 Sep; 22(5):932-940. PubMed ID: 30815759
[TBL] [Abstract][Full Text] [Related]
14. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
Matsubara D; Ishikawa S; Sachiko O; Aburatani H; Fukayama M; Niki T
Am J Pathol; 2010 Nov; 177(5):2191-204. PubMed ID: 20934974
[TBL] [Abstract][Full Text] [Related]
15. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
16. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
[TBL] [Abstract][Full Text] [Related]
18. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
20. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
